What question did this study set out to answer?

To investigate the binding interaction between heparan sulfate glycosaminoglycan and beta-amyloid peptide in Alzheimer's disease.

June 1, 1994Neuroreport

Binding of heparan sulfate glycosaminoglycan to β-amyloid peptide

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial demonstrates binding of heparan sulfate to beta-amyloid in Alzheimer’s disease, suggesting therapeutic potential.

To investigate the binding interaction between heparan sulfate glycosaminoglycan and beta-amyloid peptide in Alzheimer's disease.
Conducted binding assays with heparan sulfate glycosaminoglycan and proteoglycan.
Evaluated inhibitory effects of sulfated compounds like heparin and dextran sulfate.
Heparan sulfate glycosaminoglycan and proteoglycan showed significant binding to beta-amyloid peptide.
Binding was inhibited by other sulfated compounds, indicating potential therapeutic roles.

Leveugle et al. (1994) studied this question.

View Full Paper

Ask AI

Bookmark